Boston Scientific Corporation
Health Care · Health Care Equipment
Structural: medical-device compounder levered to two procedural growth engines - Watchman LAA closure (AFib stroke prevention) and FARAPULSE pulsed field ablation (AFib first-line). PFA is the fastest device launch in EP history; FARAPULSE captured majority US share within 12 months of approval and is cannibalising RF/cryo from $JNJ and $MDT.
Watchman compounds mid-teens on AFib prevalence + guideline tailwind. Endoscopy + urology (Rezum, SpaceOAR) provide non-cardio diversification.
PFA TAM expanding from paroxysmal to persistent AFib (FDA expansion pending); Watchman penetration <15% of eligible AFib population; pipeline (Watchman FLX Pro, AVANT GUARD trial) extends franchise; gross margin mix-up as PFA scales; M&A optionality (Axonics-style tuck-ins).
$JNJ Varipulse + $MDT PulseSelect closing the PFA gap with bigger sales forces; Watchman growth decelerates as easy AFib pool depletes; capital-intensive consumable mix; hospital capex pressure if rate cycle re-tightens; valuation premium (~30x fwd EPS) leaves no margin for execution slip.
No major news in the last 7 days for BSX - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.